Is lipoprotein(a) testing relevant in cardiovascular risk stratification?
Authors:
M. Kozárová 1; J. Tokarčík 1; A. Lacková 2; M. Valiková Bavoľárová 3; Z. Kozárová 4; R. de la Riva Ortiz 4; A. Ürgeová 1; Z. Kozelová 1
Authors‘ workplace:
Univerzita Pavla Jozefa Šafárika a Univerzitná nemocnica L. Pasteura, Košice IV. interná klinika, Prednosta: MUDr. Martin Javorský, PhD., MPH
1; Neurologické oddelenie UNLP Košice, Primár: MUDr. Marián Bali Hudák, MPH
2; Klinika pracovného lekárstva a klinickej toxikológie UPJŠ LF a UNLP, Prednosta: prof. MUDr. Ľubomír Legáth, PhD.
3; Lekárska fakulta UPJŠ Košice , Dekan: prof. MUDr. Peter Jarčuška, PhD.
4
Published in:
Prakt. Lék. 2026; 106(2): 51-59
Category:
Of different specialties
Overview
Lipoprotein(a) [Lp(a)] is an LDL-like lipoprotein particle composed of apolipoprotein B100 covalently bound to apolipoprotein(a). Currently, Lp(a) is considered an established genetically determined independent risk factor for atherosclerotic cardiovascular diseases and calcifying aortic stenosis. Approximately 20% of the population has Lp(a) levels exceeding 50 mg/dL (≈ 105 nmol/L). The 2025 ESC/EAS dyslipidaemia update recommends measuring Lp(a) at least once in every individual during their lifetime. According to a recent legislative amendment, since 2026, Lp(a) measurement in the Czech Republic has become part of preventive examinations performed by general practitioners in patients with high cardiovascular risk. The aim of this paper is to evaluate the significance of Lp(a) in cardiovascular risk stratification, its genetic background, pathophysiological mechanisms, and therapeutic perspectives.
Keywords:
lipoprotein(a) – atherosclerotic cardiovascular disease – cardiovascular risk stratification – LPA gene
Sources
1. Berg K. A new serum type system in man – the Lp system. Acta Pathol Microbiol Scand. 1963; 59 : 369–382.
2. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992; 90 : 52–60.
3. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022; 43(39): 3925–3946.
4. Albers JJ, Slee A, O’Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes with simvastatin and niacin therapy in the AIM-HIGH trial. J Am Coll Cardiol. 2013; 62(17): 1580–1584.
5. Björnsson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an Apolipoprotein B–based genetic analysis. J Am Coll Cardiol. 2024; 83(3): 385 – 395.
6. Marston NA, Melloni GEM, Murphy SA, et al. Per-particle cardiovascular risk of lipoprotein(a) vs non–lipoprotein(a) apolipoprotein b–containing lipoproteins. J Am Coll Cardiol. 2024; 83(3): 470–472.
7. Lackova A, Gdovinova Z, Kozarova M, et al. Lipoprotein (a) concentration as a risk factor for ischaemic stroke and its subtypes. Neurol Neurochir Pol. 2024; 58(3): 316–322.
8. Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: A compass for future health. J Am Coll Cardiol. 2022; 80 : 2361–2371.
9. Mach F, Baigent C, Catapano AL, et al. Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025; 46(42): 4359–4378.
10. Kronenberg F, Mora S, Stroes ESG, et al. Brussels international declaration on lipoprotein(a) testing and management. Atherosclerosis 2025; 119218.
11. Kozarova M, Lackova A, Kozelova Z, Tomco L. Lipoprotein (a): a novel cardiovascular risk factor. Balkan Med J. 2023; 40(4): 234–235.
12. Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023; 374 : 107–120.
13. Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017; 69 : 692–711.
14. Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular diseases: A genetic epidemiological perspective. Atherosclerosis 2022; 349 : 7–16.
15. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246 : 904–910.
16. Lieb W, Kraft HG, Utermann G. Lipoprotein(a) and evolution of apolipoprotein(a). J Lipid Res. 2004; 45 : 1047–1056.
17. Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016; 30 : 87–100.
18. Sandholzer C, Boerwinkle E, Saha N, et al. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population. J Clin Invest. 1992; 89 : 1040–1046.
19. Li Y, Luke MM, Shiffman D, et al. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011; 4 : 565–573.
20. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361 : 2518–2528.
21. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014; 63 : 470–477.
22. Koch W, Mueller JC, Schrempf M, et al. Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(a) gene. Ann Hum Genet. 2013; 77 : 47–55.
23. Tian LX, Zhao XM, Li L, et al. Relationships of polymorphisms of transforming growth factor-β and LPA genes with coronary heart disease and in-stent restenosis in elderly patients. J Chin Pract Diagn Ther. 2024; 38 : 464–467.
24. Lin ZN, Jia YH, Chen SF. Meta-analysis of the association between lipoprotein(a) gene polymorphism and coronary heart disease. Chin J Arterioscler. 2022; 30 : 152–160.
25. Volgman AS, Koschinsky ML, Mehta A, et al. Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk. J Am Heart Assoc. 2024; 13(12): e033654.
26. Ferretti G, Bacchetti T, Johnston TP, et al. Lipoprotein(a): A missing culprit in atherothrombosis? J Cell Physiol. 2018; 233 : 2966–2981.
27. Nordestgaard AT, Chasman DI, Moorthy V, et al. Thirty-year risk of cardiovascular disease among healthy women according to clinical thresholds of lipoprotein(a). JAMA Cardiol. 2026; 11(2): 175–185.
28. Hategeka C, Benjamin EJ, Preis SR. Association of lipoprotein(a) with atrial fibrillation in the Framingham Heart Study. JACC Advances 2025; 4(12 Pt 2): 102343.
29. Sun D, Cao YX, Li S, et al. A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia. Clin Cardiol. 2019; 42(10): 988–994.
30. Zhu L, Fang Y, Gao B, et al. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease. BMC Cardiovasc Disord. 2022; 22(1): 474.
31. De Los Reyes C, Rikhi RR, Doherty S, et al. Current clinical trials for treating elevated lipoprotein(a). Curr Cardiovasc Risk Rep. 2025; 19(1): 7.
32. Tsimikas S. Lipoprotein(a) in the year 2024: a look back and a look ahead. Arterioscler Thromb Vasc Biol. 2024; 44(7): 1485 – 1490.
33. Greco A, Finocchiaro S, Spagnolo M, et al. Lipoprotein(a) as a pharmacological target: premises, promises, and prospects. Circulation. 2025; 151(6): 400–415.
34. Vinci P, Di Girolamo FG, Panizon E, et al. Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health 2023; 20(18): 6721.
35. Momtazi-Borojeni AA, Katsiki N, Pirro M, et al. Dietary natural products as emerging lipoprotein(a)-lowering agents. J Cell Physiol. 2019; 234(8): 12581–12594.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2026 Issue 2
Most read in this issue
- Is lipoprotein(a) testing relevant in cardiovascular risk stratification?
- Pokyny pro autory časopisu Praktický lékař Časopis pro další vzdělávání lékařů
- Use of modern bioanalytical methods to determine the composition of solid biological samples
- Level of awareness of women about HPV vaccination by age of women